Tralokinumab

Summary

Tralokinumab (CHEMBL1743081) is an approved antibody (ATC D11AH07); indicated across 7 conditions including atopic eczema and asthma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: D11AH07
• Indications: 7 conditions
• Clinical trials: 34

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743081
Name	Tralokinumab
Type	Antibody
Max phase	4
ATC	D11AH07

Also known as: Adtralza, Adbry, CAT-354, Tralokinumab, TRALOKINUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
atopic eczema	4	MONDO:0004980	EFO:0000274
asthma	3	MONDO:0004979	MONDO:0004979
alopecia areata	2	MONDO:0005340	EFO:0004192
ulcerative colitis	2	MONDO:0005101	EFO:0000729
idiopathic pulmonary fibrosis	2	MONDO:0800504	EFO:0000768
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 34.

Phase distribution

Phase	Trials
PHASE3	14
PHASE2	10
PHASE1	5
Not specified	3
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07352566	PHASE4	NOT_YET_RECRUITING	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT06773455	PHASE4	TERMINATED	Tralokinumab for Dupilumab Failures
NCT06311682	PHASE3	RECRUITING	A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT02161757	PHASE3	COMPLETED	A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
NCT02194699	PHASE3	COMPLETED	A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
NCT02281357	PHASE3	COMPLETED	Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma
NCT02902809	PHASE3	TERMINATED	A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
NCT03131648	PHASE3	COMPLETED	Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)
NCT03160885	PHASE3	COMPLETED	Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)
NCT03363854	PHASE3	COMPLETED	Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3
NCT03526861	PHASE3	COMPLETED	Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).
NCT03587805	PHASE3	COMPLETED	Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
NCT03761537	PHASE3	COMPLETED	Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7
NCT04587453	PHASE3	COMPLETED	Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis
NCT05194540	PHASE3	COMPLETED	Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)
NCT05958407	PHASE3	COMPLETED	A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
NCT00640016	PHASE2	TERMINATED	A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma
NCT00873860	PHASE2	COMPLETED	Study to Evaluate the Safety and Efficacy of CAT-354
NCT01402986	PHASE2	COMPLETED	A Safety and Efficacy Study of Tralokinumab in Adults With Asthma
NCT01482884	PHASE2	COMPLETED	Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis
NCT01629667	PHASE2	TERMINATED	A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
NCT02449473	PHASE2	COMPLETED	Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids
NCT02684097	PHASE2	COMPLETED	A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata
NCT03562377	PHASE2	COMPLETED	Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)
NCT04556461	PHASE2	COMPLETED	Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function
NCT05388760	PHASE2	COMPLETED	Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
NCT00974675	PHASE1	TERMINATED	A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate Asthma
NCT01093040	PHASE1	COMPLETED	A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects
NCT01592396	PHASE1	COMPLETED	A Phase 1, Open-label Study to Investigate the Pharmacokinetics of Tralokinumab (CAT-354) in Adolescents With Asthma
NCT02085473	PHASE1	COMPLETED	A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers
NCT03556592	PHASE1	COMPLETED	Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4
NCT03358693	Not specified	RECRUITING	Molecular Signatures in Inflammatory Skin Disease
NCT05938478	Not specified	RECRUITING	Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
NCT07444801	Not specified	RECRUITING	Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).